Characterisation of normal and cancer stem cells: One experimental paradigm for two kinds of stem cells

BioEssays

Volumn 31, Issue 9, 2009, Pages 993-1001

  Mayol, Jean François ^a   Loeuillet, Corinne ^b   Hérodin, Francis ^a   Wion, Didier ^c  

^a CENTRE DE RECHERCHES   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

Cancer stem cell; FACS; Side population

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; HOE 33342; VERAPAMIL;

ARTICLE; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; CELL ASSAY; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL SURFACE; EXPERIMENTAL STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GOLD STANDARD; IMMUNOPHENOTYPING; NONHUMAN; REGENERATIVE MEDICINE; TARGET CELL DESTRUCTION; TISSUE REGENERATION; TUMOR XENOGRAFT;

ANIMALIA;

ANIMALS; BIOLOGICAL MARKERS; CELL SEPARATION; HUMANS; NEOPLASTIC STEM CELLS; PHENOTYPE; STEM CELLS;

EID: 70349975991     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900041     Document Type: Article

References (84)

1. Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006. 66: 9339-9344.
2. Reya, T., Morrison, S. J., Clarke, M. F. and Weissman, I. L., Stem cells, cancer, and cancer stem cells. Nature 2001. 414: 105-111.
3. Visvader, J. E. and Lindeman, G. J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008. 8: 755-768.
4. Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., et al. Efficient tumour formation by single human melanoma cells. Nature 2008. 456: 593-598.
5. Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006. 12: 5615-5621.
6. Li, F., Tiede, B., Massague, J. and Kang, Y., Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007. 17: 3-14.
7. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. and Kirchner, T., Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005. 5: 744-749.
8. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007. 1: 313-323.
9. Eyler, C. E. and Rich, J. N., Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008. 26: 2839-2845.
10. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. and Mulligan, R. C., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996. 183: 1797-1806.
11. Kondo, T., Setoguchi, T. and Taga, T., Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004. 101: 781-786.
12. Berenson, R. J., Andrews, R. G., Bensinger, W. I., Kalamasz, D., Knitter, G., et al. Antigen CD34R marrow cells engraft lethally irradiated baboons. J Clin Invest 1988. 81: 951-955.
13. Osawa, M., Hanada, K., Hamada, H. and Nakauchi, H., Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996. 273: 242-245.
14. Miraglia, S., Godfrey, W., Yin, A. H., Atkins, K., Warnke, R., et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997. 90: 5013-5021.
15. Wu, A., Oh, S.,Wiesner, S. M., Ericson, K., Chen, L., et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008. 17: 173-184.
16. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004. 101: 14228-14233.
17. Patrawala, L., Calhoun, T., Schneider-Broussard, R., Zhou, J., Claypool, K., et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005. 65: 6207-6219.
18. Loewe, H. and Urbanietz, J., Basic-substituted 2,6-bisbenzimidazole derivates, a novel class of substances with chemotherapeutic activity. Arzneimittelforschung 1974. 24: 1927-1933.
19. Arndt-Jovin, D. J. and Jovin, T. M., Analysis and sorting of living cells according to deoxyribonucleic acid content. J Histochem Cytochem 1977. 25: 585-589.
20. Petersen, T. W., Ibrahim, S. F., Diercks, A. H. and van den Engh, G., Chromatic shifts in the fluorescence emitted by murine thymocytes stained with Hoechst 33342. Cytometry Part A 2004. 60A: 173-181.
21. Scharenberg, C. W., Harkey, M. A. and Torok-Storb, B., The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002. 99: 507-512.
22. Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A 2002. 99: 12339-12344.
23. Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A. M., Sampath, J., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001. 7: 1028-1034.
24. Jonker, J. W., Freeman, J., Bolscher, E., Musters, S., Alvi, A. J., et al. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005. 23: 1059-1065.
25. Dean, M., Fojo, T. and Bates, S., Tumour stem cells and drug resistance. Nat Rev Cancer 2005. 5: 275-284.
26. Platet, N., Mayol, J. F., Berger, F., Herodin, F. and Wion, D., Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Lett 2007. 581: 1435-1440.
27. Smalley, M. J. and Clarke, R. B., The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia 2005. 10: 37-47.
28. Durand, R. E. and Olive, P. L., Cytotoxicity, Mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem 1982. 30: 111-116.
29. Fried, J., Doblin, J., Takamoto, S., Perez, A., Hansen, H., et al. Effects of Hoechst 33342 on survival and growth of two tumor cell lines and on hematopoietically normal bone marrow cells. Cytometry 1982. 3: 42-47.
30. Adamski, D., Mayol, J. F., Platet, N., Berger, F., Herodin, F., et al. Effects of Hoechst 33342 on C2C12 and PC12 cell differentiation. FEBS Lett 2007. 581: 3076-3080.
31. Steuer, B., Breuer, B. and Alonso, A., Differentiation of EC cells in vitro by the fluorescent dye Hoechst 33342. Exp Cell Res 1990. 186: 149-157.
32. Zhong, Y., Zhou, C., Ma, W., Wang, D., Guo, S., et al. Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342. Biochem Biophys Res Commun 2007. 364: 338-343.
33. Chen, A. Y., Yu, C., Bodley, A., Peng, L. F. and Liu, L. F., A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993. 53: 1332-1337.
34. Kondo, K., Tsuneizumi, K., Watanabe, T. and Oishi, M., Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases. Cancer Res 1991. 51: 5398-5404.
35. Larsen, A. K., Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation. Ann Oncol 1994. 5: 679-688.
36. Zhang, X. and Kiechle, F. L., Hoechst 33342 induces apoptosis and alters tata box binding protein/DNA complexes in nuclei from BC3H-1 myocytes. Biochem Biophys Res Commun 1998. 248: 18-21.
37. Moshaver, B., van Rhenen, A., Kelder, A., van der Pol, M., Terwijn, M., et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008. 26: 3059-3067.
38. Wulf, G. G., Wang, R. Y., Kuehnle, I., Weidner, D., Marini, F., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001. 98: 1166-1173.
39. Noguchi, K., Katayama, K., Mitsuhashi, J. and Sugimoto, Y., Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 2009. 61: 26-33.
40. Bleau, A. M., Hambardzumyan, D., Ozawa, T., Fomchenko, E. I., Huse, J. T., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009. 4: 226-235.
41. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. and Clarke, M. F., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003. 100: 3983-3988.
42. Dalerba, P., Dylla, S. J., Park, I. K., Liu, R., Wang, X., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007. 104: 10158-10163.
43. O'Brien, C. A., Pollett, A., Gallinger, S. and Dick, J. E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007. 445: 106-110.
44. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007. 445: 111-115.
45. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., et al. Identification of human brain tumour initiating cells. Nature 2004. 432: 396-401.
46. Zhang, S., Balch, C., Chan, M. W., Lai, H. C., Matei, D., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008. 68: 4311-4320.
47. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994. 367: 645-648.
48. Monzani, E., Facchetti, F., Galmozzi, E., Corsini, E., Benetti, A., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007. 43: 935-946.
49. Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008. 15: 504-514.
50. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. and Maitland, N. J., Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005. 65: 10946-10951.
51. Shmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008. 118: 2111-2120.
52. Krause, D. S., Fackler,M. J., Civin, C. I. and May, W. S., CD34: structure, biology, and clinical utility. Blood 1996. 87: 1-13.
53. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006. 444: 756-760.
54. Blazek, E. R., Foutch, J. L. and Maki, G., Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007. 67: 1-5.
55. Yao, X. H., Ping, Y. F., Chen, J. H., Xu, C. P., Chen, D. L., et al. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 2008. 215: 369-376.
56. Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004. 23: 5748-5758.
57. Shapiro, H. M., Practical flow cytometry. 4th ed. New-York, Wiley-Liss, 2003.
58. Lee, J. A., Spidlen, J., Boyce, K., Cai, J., Crosbie, N., et al. MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry A 2008. 73: 926-930.
59. Schwartz, A. and Fernandez-Repollet, E., Quantitative flow cytometry. Clin Lab Med 2001. 21: 743-761.
60. Wu, C. and Alman, B. A., Side population cells in human cancers. Cancer Lett 2008. 268: 1-9.
61. Srivastava, V. K. and Nalbantoglu, J., Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A 2008. 73: 940-948.
62. Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007. 67: 4010-4015.
63. Joo, K. M., Kim, S. Y., Jin, X., Song, S. Y., Kong, D. S., et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008. 88: 808-815.
64. Ogden, A. T., Waziri, A. E., Lochhead, R. A., Fusco, D., Lopez, K., et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008. 62: 505-514; discussion 514-515.
65. Wang, J., Sakariassen, P. O., Tsinkalovsky, O., Immervoll, H., Boe, S. O., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008. 122: 761-768.
66. Merlo, L. M., Pepper, J. W., Reid, B. J. and Maley, C. C., Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006. 6: 924-935.
67. Nowell, P. C., The clonal evolution of tumor cell populations. Science 1976. 194: 23-28.
68. Griguer, C. E., Oliva, C. R., Gobin, E., Marcorelles, P., Benos, D. J., et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008. 3: e3655.
69. Platet, N., Liu, S. Y., Atifi, M. E., Oliver, L., Vallette, F. M., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007. 258: 286-290.
70. Bene, M. C., Immunophenotyping of acute leukaemias. Immunol Lett 2005. 98: 9-21.
71. Di Noto, R., Mirabelli, P. and Del Vecchio, L., Flow cytometry analysis of acute promyelocytic leukemia: the power of 'surface hematology'. Leukemia 2007. 21: 4-8.
72. Engelhardt, M., Lubbert, M. and Guo, Y., CD34(+) or CD34(-): which is the more primitive? Leukemia 2002. 16: 1603-1608.
73. Morita, Y., Ema, H., Yamazaki, S. and Nakauchi, H., Non-side-population hematopoietic stem cells in mouse bone marrow. Blood 2006. 108: 2850-2856.
74. Garcion, E., Naveilhan, P., Berger, F. and Wion, D., Cancer stem cells: Beyond Koch's postulates. Cancer Lett 2009. 278: 3-8.
75. Hill, R. P., Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 66: 1891-1895; 2006. discussion 1890.
76. Sell, S., Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004. 51: 1-1-28.
77. Koch, R., Zur Untersuchung von pathogen Organismen. Mitt Kaiserlichen Gesundheitsamte 1881. 1: 25-26.
78. Petri, R. J., Eine kliene Modification des Koch'shen Platten-verfahrens. Zentralbl Bakteriol Parasitenkd 1887. 1: 279-280.
79. Vandercappellen, J., Van Damme, J. and Struyf, S., The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008. 267: 226-244.
80. Benelli, R. and Albini, A., In vitro models of angiogenesis: the use of Matrigel. Int J Biol Markers 1999. 14: 243-246.
81. Albini, A., Benelli, R., Noonan, D. M. and Brigati, C., The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol 2004. 48: 563-571.
82. Hu, M. and Polyak, K., Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008. 18: 27-34.
83. Bissell, M. J. and Labarge, M. A., Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005. 7: 17-23.
84. van Os, R., Kamminga, L. M. and de Haan, G., Stem cell assays: something old, something new, something borrowed. Stem Cells 2004. 22: 1181-1190.